Drug Profile
Research programme: HDAC inhibitors - OnKure Therapeutics
Alternative Names: ONK-102Latest Information Update: 28 Mar 2023
Price :
$50
*
At a glance
- Originator OnKure Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action HDAC1 protein inhibitors; HDAC6 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer